Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Hirotaka Morishima"'
Publikováno v:
Allergology International, Vol 58, Iss 4, Pp 573-583 (2009)
Background: B7-H2 is a ligand for the inducible costimulator (ICOS). The aim of this study was to examine the expression and function of B7-H2 in human airway smooth muscle (ASM) cells and compare them with those of CD40 or OX40 ligand (OX40L). Metho
Externí odkaz:
https://doaj.org/article/3fd8eb62f87446a4af6c4e75d96ddc6e
Autor:
Miki Yamaguchi, Hiroyuki Yasojima, Fuminori Aki, Fumie Fujisawa, Makiko Mizutani, Takahiro Nakayama, Katsuhide Yoshidome, Jun Yamamura, Junji Tsurutani, Yoshifumi Komoike, Tomomi Yamada, Hirotaka Morishima, Satoshi Morita, Mitsuhiko Iwamoto, Tsutomu Takashima, Norikazu Masuda, Masahiko Ikeda, Tetsuhiro Yoshinami
Publikováno v:
Cancer Research. 80:P3-12
Background: In the International Consensus Conference Guidelines for Advanced Breast Cancer, most experts agreed that the maintenance endocrine therapy after induction chemotherapy was reasonable. The combination therapy of bevacizumab (B) and paclit
Autor:
Norihiro Hokimoto, Risa Terasawa, Tsutomu Takashima, Takashi Morimoto, Shintaro Michishita, Hirotaka Morishima, Shinichiro Kashiwagi, Junna Sakane, Yukihiro Nishida, Mitsuhiko Iwamoto, Satoru Noda, Nobuki Matsunami, Toshikatsu Nitta, Hiruya Fujioka, Kosei Kimura, Satoru Tanaka, Ayana Ikari, Nayuko Sato, Toshihiro Kobayashi, Yukie Tauchi, Naofumi Oda, Yuka Asano, Kanako Kawaguchi
Publikováno v:
Cancer Research. 80:P2-16
Background: Neoadjuvant anti-HER2 target agents combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has been c
Autor:
Miki Yamaguchi, Tomomi Yamada, Yoshifumi Komoike, Takahiro Nakayama, Mitsuhiko Iwamoto, Makiko Mizutani, Jun Yamamura, Norikazu Masuda, Katsuhide Yoshidome, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Fuminori Aki, Tsutomu Takashima, Satoshi Morita, Hirotaka Morishima, Fumie Fujisawa, Junji Tsurutani, Masahiko Ikeda
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4399, p 4399 (2021)
Volume 13
Issue 17
Cancers, Vol 13, Iss 4399, p 4399 (2021)
Volume 13
Issue 17
Optimal treatment strategies for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC) remain uncertain. We investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after ind
Autor:
Junichi, Hasegawa, Mitsuyoshi, Tei, Tae, Matsumura, Toshinori, Sueda, Haruna, Furukawa, Chikato, Koga, Masaki, Wakasugi, Hiromichi, Miyagaki, Ryohei, Kawabata, Naofumi, Oda, Hirotaka, Morishima, Hideaki, Miwa, Junzo, Shimizu
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(2)
A 64-year-old man was referred to our hospital to determine the cause of fecal occult blood. Colonoscopy revealed a type Ⅱtumor located in the ascending colon. Histopathologic analysis of the tumor biopsy specimen revealed moderately differen- tiat
Autor:
K Anno, M Shimada, M Kagawa, Naofumi Oda, T Ryo, Fumine Tsukamoto, M Udo, Hirotaka Morishima, Yukihiro Nishida, Nobuki Matsunami, Katsuhide Yoshidome, T Shimo, R Tsunashima, Takashi Morimoto
Publikováno v:
Cancer Research. 78:P6-11
A brief background discussion. Nanoparticle albumin-bound paclitaxel (nab-PTX) has been developed under the concept of improved drug delivery. nab-PTX has been shown to significantly increase progression-free survival compared with solvent-based pacl
Autor:
Nayuko Sato, Kosei Kimura, Yuka Asano, Yukihiro Nishida, Shinichiro Kashiwagi, Tsutomu Takashima, Takashi Morimoto, Ayana Ikari, Toshihiro Kobayashi, Satoru Noda, Yukie Tauchi, Hiroya Fujioka, Naofumi Oda, Mitsuhiko Iwamoto, Nobuki Matsunami, Satoru Tanaka, Risa Terasawa, Hirotaka Morishima, Junna Sakane, Kanako Kawaguchi, Toshikatsu Nitta, Norihiro Hokimoto, Shintaro Michishita
Publikováno v:
Cancer chemotherapy and pharmacology. 83(6)
Neoadjuvant trastuzumab combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has been considered as a treatment
Publikováno v:
Journal of Clinical Oncology. 38:e12557-e12557
e12557 Background: Atezolizumab was approved for PD-L1-positive advanced recurrent triple negative breast cancer. However, it is controversial about when and when to measure PD-L1. Here we retrospectively reaearched how PD-L1 positivity rates in biop
Autor:
Takashi Morimoto, Nobuki Matsunami, Toshihiro Kobayashi, Satoru Tanaka, Hirotaka Morishima, Katsuhide Yoshidome, Kosei Kimura, Daigo Yamamoto, Yu Tsubota, Takashi Nomura, Kazuhisa Uchiyama, Mitsuhiko Iwamoto
Publikováno v:
Clinical Breast Cancer. 15:191-196
We treated patients with operable human epidermal growth factor receptor 2-positive breast cancer with neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel plus trastuzumab. Of the 44 patients, 49% achieved a pathologi
Autor:
Junichi, Hasegawa, Shingo, Noura, Masaki, Hirota, Tae, Matsumura, Akinobu, Yasuyama, Akihiro, Takata, Chikato, Koga, Masahiro, Murakami, Chizu, Kameda, Naofumi, Oda, Ryohei, Kawabata, Hirotaka, Morishima, Junzo, Shimizu, Nobuki, Matsunami
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 43(12)
A 51-year-oldwoman with lung, liver, andd istant lymph node metastases from sigmoidcolon cancer was treatedusing TAS-102 with bevacizumab as fourth-line chemotherapy. There was a 35%decrease in the size of target lesions after the first 4 cycles of t